Despite decades of research, no disease-modifying therapy has been approved for corticobasal syndrome (CBS). However, the therapeutic pipeline has expanded significantly in recent years, with multiple agents targeting the underlying tau pathology, neuroinflammation, and neuronal dysfunction. This page provides an in-depth analysis of emerging treatments currently in development for CBS.
Bepranemab (UCB0107)
- Mechanism: Humanized monoclonal antibody targeting tau protein
- Phase: Phase II clinical trials
- Status: Currently recruiting CBS patients
- Target: Extracellular tau to prevent propagation
- ClinicalTrials.gov: NCT04658199
- Reference: Boxer et al., 2020
Tilavonemab (ABBV-8E12)
- Mechanism: Anti-tau antibody targeting aggregated tau
- Phase: Phase II completed
- Status: Completed but no longer in active development for CBS
- Results: Did not meet primary endpoints in PSP, limited data in CBS
Semorinemab
- Mechanism: Tau-directed antibody
- Phase: Tested in CBS/PSP
- Status: Negative results in Phase II
- Reference: Hoglinger et al., 2022
Tau immunotherapy aims to:
- Bind extracellular tau preventing neuronal uptake
- Enhance clearance of tau aggregates
- Prevent trans-synaptic spread of pathological tau
- CBS patient heterogeneity (multiple underlying pathologies)
- Blood-brain barrier penetration
- Need for biomarker-driven patient selection
- Optimal timing of intervention (pre-symptomatic vs. symptomatic)
FNP-223 (Ferrer) — See dedicated page
- Mechanism: OGA (O-GlcNAcase) inhibitor — increases tau O-GlcNAcylation competing with pathological phosphorylation
- Phase: PROSPER trial (NCT06355531)
- Status: Enrollment complete (n=220 PSP patients)
- Target: O-GlcNAcase enzyme, increases protective tau O-GlcNAcylation
Methylene Blue/LTMX
- Mechanism: Inhibits tau aggregation
- Status: Limited data specific to CBS
- Reference: Wischik et al., 2021
- Note: Historical compound with mixed results
TPI-287 (Abeotaxane)
- Mechanism: Microtubule stabilizer, protects neuronal architecture
- Phase: Phase I randomized clinical trial
- Status: Completed
- Publication: JAMA Neurology (2020), PMID: 31710340
- Finding: Assessed safety, tolerability, and pharmacodynamics
- Significance: One of few Phase I trials specifically targeting CBS
Lithium
- Mechanism: GSK3beta inhibitor
- Potential: May reduce tau phosphorylation
- Status: Not studied specifically in CBS
- Note: Known toxicity limits clinical application
Tideglusib
- Mechanism: Non-competitive GSK3beta inhibitor
- Status: Studied in PSP (negative results)
- Relevance: Not studied specifically in CBS
AMX0035 (Relyvrio)
- Mechanism: Fixed-dose combination of sodium phenylbutyrate (HDAC inhibitor) + tauroursodeoxycholic acid (mitochondrial protector)
- Target: Mitochondrial dysfunction, autophagy impairment, ER stress
- Phase: Phase 2b/3 ORION trial (NCT06122662)
- Status: Tested in PSP, may include CBS patients
- Approval: FDA-approved for ALS
- Significance: First combination therapy in late-stage testing for 4R tauopathies
- Reference: Targeting key pathological pathways in CBS
Coenzyme Q10
- Dose: 300-2400mg daily
- Mechanism: Supports mitochondrial function
- Evidence: Generally well-tolerated
- Reference: Niemann et al., 2020
NADAPT Study (NCT06162013)
- Mechanism: NAD+ precursor supplementation
- Target: Cellular energy metabolism
- Phase: Phase 2 randomized double-blind trial
- Status: Recruiting atypical parkinsonism including CBS
- Rationale: Strong preclinical evidence for NAD+ depletion in CBS
- Significance: Novel disease-modifying approach targeting energy metabolism
Microglia-Modulating Approaches
- Target: Neuroinflammation, a key feature of CBS pathology
- Status: Preclinical and early clinical development
- Approach: Modulating microglial activation to reduce harmful inflammation
Neurologic Stem Cell Treatment Study (NCT02795052)
- Mechanism: Intravenous and intrathecal neural stem cell administration
- Phase: Phase 1
- Status: Recruiting for PSP and CBD
- Assessment: Adverse events and preliminary efficacy over 24 months
- Reference: Pascual et al., 2021
- Goal: Replace damaged neurons or provide neurotrophic support
NCT07291687
- Mechanism: Non-invasive brain stimulation modulating cortical excitability
- Phase: Device study
- Status: Recruiting
- Target: Motor function improvement
- Approach: Combined with motor training
NCT04468932
- Mechanism: Non-invasive brain stimulation
- Phase: Phase 2
- Status: Recruiting (PSP, may inform CBS)
- Target: Motor and cognitive symptoms
NCT05653778
- Mechanism: Non-invasive neuromodulation using electrical signals
- Target: Neuropathic pain in CBS
- Phase: Pilot trial
- Significance: Addresses quality of life issue in CBS patients
NCT06174948
- Mechanism: Vibrotactile cueing device for gait freezing
- Status: Recruiting (PD and related disorders)
- Institution: Queen Mary University, London
- Potential: May benefit CBS patients with movement initiation difficulties
Exenatide
- Mechanism: GLP-1 receptor agonist
- Phase: Phase 3
- Status: Recruiting (PD, may include CBS)
- Rationale: Neuroprotective properties demonstrated in preclinical models
- Reference: Currently in trials for Parkinson's disease
Metformin
- Potential: Neuroprotective properties
- Evidence: Observational data suggesting reduced neurodegeneration risk
- Status: Not specifically studied in CBS
Statins
- Evidence: Mixed epidemiological evidence
- Status: No randomized trial data in CBS
Recent advances in CBS diagnosis and biomarker development are enabling more targeted clinical trials:
- Tau PET Imaging: Selecting patients with confirmed tau pathology
- CSF Biomarkers: Neurofilament light chain (NfL), tau species
- Genetic Testing: Identifying GRN, MAPT, and other relevant mutations
| Biomarker Type |
Utility |
Examples |
| Tau PET |
Path burden |
[18F]ABBV-964i, [18F]ABBV-965i, [18F]PI-2620 |
| CSF |
Neurodegeneration |
NfL, p-tau, t-tau |
| Blood |
Accessible markers |
p-tau217, NfL |
| Genetic |
Patient stratification |
GRN, MAPT, C9orf72 |
- Heterogeneous pathology: CBS results from multiple underlying diseases
- Small patient population: Rare disease limits trial enrollment
- Diagnostic uncertainty: Clinical diagnosis may not predict pathology
- Rapid progression: Short window for therapeutic intervention
- Overlapping phenotypes: CBS-PSP-FTD spectrum
- Subtype stratification: Using biomarkers to select homogeneous populations
- Adaptive designs: More efficient trial structures
- Remote monitoring: Digital biomarkers for continuous assessment
- Multi-arm trials: Testing multiple agents simultaneously